

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Patent No. : 7,435,256 B2 Issued: October 14, 2008  
Applicant : Eric B. Stenzel  
Serial No. : 10/701,455  
Filed: : November 6, 2003  
Title: : METHOD AND APPARATUS FOR CONTROLLED DELIVERY OF  
ACTIVE SUBSTANCE  
Art Unit : 3738 Confirmation No. 8547  
Examiner : Suzette Jamie J. Gherbi

**REQUEST FOR CERTIFICATE OF CORRECTION PURSUANT TO 37 C.F.R. §1.323**

**Attn: Certificate of Corrections Branch**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SIR:

Patentee hereby requests that the enclosed Certificate of Correction be issued for the above Patent. The following errors that appear in this patent are of a clerical, typographical or minor nature or character and occurred in good faith. Correction thereof does not involve changes in the patent as would constitute new matter or would require reexamination. In particular:

Column 1, line 55, "site the" should be changed to --site in the--;

Column 4, line 4, "(BAYHDROL®, etc)" should be changed to --(BAYHYDROL®,  
etc)--;

Column 4, line 6, "collage" should be changed to --collagen--;

Column 5, lines 54-55, "micro-coating **210**" should be changed to --micro-coating **220**--;

Column 5, line 65, “pellet **300**” should be changed to --pellet--;

Column 7, line 8, “represent” should be changed to --represented--;

Column 8, line 58, “wrapper” should be changed to --wrapped--;

Column 9, line 1, “virus” should be changed to --viruses--;

Column 9, lines 1-2, “andenoassociated virus” should be changed to -- adeno-associated virus--;

Column 9, lines 18-19, “viral, liposomes” should be changed to --viral liposomes--;

Column 9, line 43, “nitorfurantoin” should be changed to --nitrofurantoin--;

Column 9, line 45, “lisidomine” should be changed to --linsidomine--;

Column 9, line 51, “Warafin” should be changed to --warfarin--;

Column 9, line 53, “promotors” should be changed to --promoters--;

Column 9, line 55, “promotors” should be changed to --promoters--;

Column 9, line 63, “endogeneus vascoactive” should be changed to --endogenous vasoactive--;

Column 10, line 35, “(“BMP’s”) ” should be changed to --(“BMPs”)--;

Column 10, line 39, “BMP’s” should be changed to --BMPs--; and

Column 10, line 45, “DNA’s” should be changed to --DNAs--.

The Commissioner is hereby authorized to charge payment of the 37 C.F.R. §1.20(a) Certificate of Correction fee of \$100.00 to the deposit account of Kenyon & Kenyon, deposit account number 11-0600. The Commissioner is also authorized to charge any additional fees or credit any overpayment in connection with this paper to Deposit Account No. 11-0600.

Respectfully submitted,

KENYON & KENYON LLP

Dated: August 20, 2009

/Jocelyn D. Ram/  
Jocelyn D. Ram  
Reg. No. 54,898

KENYON AND KENYON LLP  
1500 K Street, N.W., Suite 700  
Washington, D.C. 20005-1257  
Tel: (202) 220-4200  
Fax: (202) 220-4201

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 1 of 1

PATENT NO. : 7,435,256 B2

APPLICATION NO.: 10/701,455

ISSUE DATE : October 14, 2008

INVENTOR(S) : Eric B. Stenzel

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 1, line 55, "site the" should be changed to --site in the--;  
Column 4, line 4, "(BAYHDROL®, etc)" should be changed to --(BAYHYDROL®, etc)--;  
Column 4, line 6, "collage" should be changed to --collagen--;  
Column 5, lines 54-55, "micro-coating 210" should be changed to --micro-coating 220--;  
Column 5, line 65, "pellet 300" should be changed to --pellet--;  
Column 7, line 8, "represent" should be changed to --represented--;  
Column 8, line 58, "wrapper" should be changed to --wrapped--;  
Column 9, line 1, "virus" should be changed to --viruses--;  
Column 9, lines 1-2, "andenoassociated virus" should be changed to -- adeno-associated virus--;  
Column 9, lines 18-19, "viral, liposomes" should be changed to --viral liposomes--;  
Column 9, line 43, "nitorfurantoin" should be changed to --nitrofurantoin--;  
Column 9, line 45, "lisidomine" should be changed to --linsidomine--;  
Column 9, line 51, "Warafin" should be changed to --warfarin--;  
Column 9, line 53, "promotors" should be changed to --promoters--;  
Column 9, line 55, "promotors" should be changed to --promoters--;  
Column 9, line 63, "endogeneus vascoactive" should be changed to --endogenous vasoactive--;  
Column 10, line 35, "(BMP's)" should be changed to --("BMPs")--;  
Column 10, line 39, "BMP's" should be changed to --BMPs--; and  
Column 10, line 45, "DNA's" should be changed to --DNAs--.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

KENYON AND KENYON  
1500 K Street, N.W., Suite 700  
Washington, D.C. 20005

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*